ALK Launches Neffy Nasal Adrenaline Spray in Canada
Event summary
- ALK launched neffy® 2 mg nasal adrenaline spray in Canada after Health Canada approval in April 2026.
- The product targets severe allergy sufferers (≥30 kg), offering a needle-free alternative to traditional auto-injectors.
- Canada is expected to become ALK’s largest market outside Europe, with up to 2.5 million potential users.
- ALK holds exclusive global commercialization rights (excluding USA, Australia, NZ, Japan, China) via 2024 agreement with ARS Pharma.
The big picture
ALK’s Canadian launch represents a strategic expansion into North America’s allergy treatment market, complementing its European footprint. The needle-free design addresses consumer hesitancy around traditional auto-injectors, potentially capturing significant share in a market where up to half of respondents lack confidence using existing solutions.
What we're watching
- Market Penetration
- Whether ALK can convert Canada’s 2.5 million severe allergy sufferers to neffy® amid existing treatment options.
- Regulatory Progress
- The pace at which Health Canada approves the pending 1 mg dosage for younger patients (15-30 kg).
- Commercial Strategy
- How ALK’s co-promotion agreement with ARS Pharma in the US will impact global market positioning.
Related topics